PL2160190T3 - Pochodne 5beta, 14beta-androstanu przydatne w leczeniu chorób będących wynikiem zwłóknienia organu - Google Patents
Pochodne 5beta, 14beta-androstanu przydatne w leczeniu chorób będących wynikiem zwłóknienia organuInfo
- Publication number
- PL2160190T3 PL2160190T3 PL08760508T PL08760508T PL2160190T3 PL 2160190 T3 PL2160190 T3 PL 2160190T3 PL 08760508 T PL08760508 T PL 08760508T PL 08760508 T PL08760508 T PL 08760508T PL 2160190 T3 PL2160190 T3 PL 2160190T3
- Authority
- PL
- Poland
- Prior art keywords
- 14beta
- 5beta
- treatment
- derivatives useful
- diseases due
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07109779 | 2007-06-07 | ||
| EP08760508.5A EP2160190B1 (en) | 2007-06-07 | 2008-06-04 | 5beta, 14beta-androstane derivatives useful for the treatment of diseases due to organ fibrosis |
| PCT/EP2008/056928 WO2008148812A1 (en) | 2007-06-07 | 2008-06-04 | 5beta, 14beta-androstane derivatives useful for the treatment of restenosis after angioplastic or endoartherectomy and diseases due to organ fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2160190T3 true PL2160190T3 (pl) | 2016-03-31 |
Family
ID=38662675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08760508T PL2160190T3 (pl) | 2007-06-07 | 2008-06-04 | Pochodne 5beta, 14beta-androstanu przydatne w leczeniu chorób będących wynikiem zwłóknienia organu |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100303896A1 (pl) |
| EP (1) | EP2160190B1 (pl) |
| JP (1) | JP5579058B2 (pl) |
| KR (1) | KR101530019B1 (pl) |
| CN (1) | CN101720224B (pl) |
| AU (1) | AU2008258521B2 (pl) |
| BR (1) | BRPI0812775B8 (pl) |
| CA (1) | CA2688079C (pl) |
| DK (1) | DK2160190T3 (pl) |
| ES (1) | ES2556731T3 (pl) |
| HK (1) | HK1140698A1 (pl) |
| HR (1) | HRP20151233T1 (pl) |
| HU (1) | HUE025599T2 (pl) |
| MX (1) | MX2009012917A (pl) |
| PL (1) | PL2160190T3 (pl) |
| PT (1) | PT2160190E (pl) |
| RS (1) | RS54459B1 (pl) |
| SI (1) | SI2160190T1 (pl) |
| WO (1) | WO2008148812A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2411015T3 (pl) * | 2009-03-23 | 2016-05-31 | Cvie Therapeutics Ltd | Pochodne 5-beta,14-beta-androstanu przydatne w leczeniu białkomoczu, stwardnienia kłębków nerkowych i niewydolności nerek |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW226375B (pl) * | 1991-10-24 | 1994-07-11 | American Home Prod | |
| AU3475693A (en) * | 1992-02-14 | 1993-09-03 | Warner-Lambert Company | Method of treating abnormal tissue proliferation by administering an angiotensin ii antagonist |
| DE4227616C2 (de) * | 1992-08-20 | 1995-04-13 | Sigma Tau Ind Farmaceuti | 17-(3-Furyl)-und 17-(4-Pyridazinyl)-5beta, 14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammemsetzungen |
| DE4232638C2 (de) * | 1992-09-29 | 1994-11-17 | Sigma Tau Ind Farmaceuti | 17-Phenyl-5beta-14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen |
| EP0863143A1 (en) * | 1993-03-24 | 1998-09-09 | American Home Products Corporation | Intermediates useful in the production of pyridopyrimidone angiotensin AII antagonists |
| WO2004089416A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| WO2006044916A2 (en) * | 2004-10-18 | 2006-04-27 | Bionaut Pharmaceuticals, Inc. | Use of na+/ k+-atpase inhibitors and antagonists thereof |
-
2008
- 2008-06-04 BR BRPI0812775A patent/BRPI0812775B8/pt not_active IP Right Cessation
- 2008-06-04 WO PCT/EP2008/056928 patent/WO2008148812A1/en active Application Filing
- 2008-06-04 PL PL08760508T patent/PL2160190T3/pl unknown
- 2008-06-04 EP EP08760508.5A patent/EP2160190B1/en active Active
- 2008-06-04 HU HUE08760508A patent/HUE025599T2/en unknown
- 2008-06-04 ES ES08760508.5T patent/ES2556731T3/es active Active
- 2008-06-04 SI SI200831539T patent/SI2160190T1/sl unknown
- 2008-06-04 MX MX2009012917A patent/MX2009012917A/es active IP Right Grant
- 2008-06-04 US US12/602,827 patent/US20100303896A1/en not_active Abandoned
- 2008-06-04 CN CN200880019175.XA patent/CN101720224B/zh not_active Expired - Fee Related
- 2008-06-04 DK DK08760508.5T patent/DK2160190T3/en active
- 2008-06-04 RS RS20150845A patent/RS54459B1/en unknown
- 2008-06-04 CA CA2688079A patent/CA2688079C/en active Active
- 2008-06-04 AU AU2008258521A patent/AU2008258521B2/en not_active Ceased
- 2008-06-04 KR KR1020097024493A patent/KR101530019B1/ko active IP Right Grant
- 2008-06-04 PT PT87605085T patent/PT2160190E/pt unknown
- 2008-06-04 JP JP2010510789A patent/JP5579058B2/ja not_active Expired - Fee Related
-
2010
- 2010-07-29 HK HK10107264.2A patent/HK1140698A1/xx not_active IP Right Cessation
-
2015
- 2015-11-16 HR HRP20151233TT patent/HRP20151233T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2160190E (pt) | 2016-01-27 |
| CA2688079C (en) | 2016-05-03 |
| CA2688079A1 (en) | 2008-12-11 |
| MX2009012917A (es) | 2010-01-14 |
| AU2008258521B2 (en) | 2013-03-28 |
| JP5579058B2 (ja) | 2014-08-27 |
| US20100303896A1 (en) | 2010-12-02 |
| ES2556731T3 (es) | 2016-01-19 |
| CN101720224A (zh) | 2010-06-02 |
| KR101530019B1 (ko) | 2015-06-18 |
| KR20100022021A (ko) | 2010-02-26 |
| AU2008258521A1 (en) | 2008-12-11 |
| BRPI0812775B1 (pt) | 2020-02-04 |
| EP2160190B1 (en) | 2015-11-04 |
| HK1140698A1 (en) | 2010-10-22 |
| WO2008148812A1 (en) | 2008-12-11 |
| SI2160190T1 (sl) | 2015-12-31 |
| CN101720224B (zh) | 2014-03-26 |
| HRP20151233T1 (hr) | 2015-12-18 |
| HUE025599T2 (en) | 2016-05-30 |
| RS54459B1 (en) | 2016-06-30 |
| DK2160190T3 (en) | 2016-01-11 |
| BRPI0812775A2 (pt) | 2014-12-02 |
| EP2160190A1 (en) | 2010-03-10 |
| JP2010529082A (ja) | 2010-08-26 |
| BRPI0812775B8 (pt) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260117A (en) | Use of placental cells to treat diseases, syndromes or conditions of the lungs | |
| IL200368A0 (en) | Treatment of diseases characterized by inflammation | |
| HK1163500A1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| HK1154382A1 (en) | Triazole derivatives useful for the treatment of diseases | |
| PL2049127T3 (pl) | N-metanokarbapochodne do leczenia chorób serca | |
| HK1144390A1 (en) | Compositions for the treatment of neoplastic diseases | |
| ZA201006752B (en) | Spiro-indole derivatives for the treatment of parasitic disease | |
| PT1988059E (pt) | Processo contínuo para a preparação de nanotubos de titanato de sódio | |
| ZA201005116B (en) | 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders | |
| IL216967B (en) | The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases | |
| EP2160100B8 (en) | Treatment of graft-versus-host disease | |
| HK1141708A1 (en) | Agent for treatment of pulmonary disease | |
| PL2056858T3 (pl) | Leczenie stanów chorobowych płuc | |
| ZA200905364B (en) | Treatment of diseases characterized by inflammation | |
| IL210290A0 (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
| EP2210621A4 (en) | COMPOSITION FOR THE TREATMENT OF JOINT DISEASES | |
| HK1158954A1 (en) | 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases | |
| EP2157089A4 (en) | THERAPEUTIC USES OF IMIDAZOL-5-CARBOXYLIC ACID DERIVATIVES | |
| PL2160190T3 (pl) | Pochodne 5beta, 14beta-androstanu przydatne w leczeniu chorób będących wynikiem zwłóknienia organu | |
| PT2278962E (pt) | Métodos para o tratamento de desordens dermatológicas | |
| GB0715257D0 (en) | Phenylthiazolylpiperazine derivatives for the treatment of nuero degenerative diseases | |
| GB0711463D0 (en) | Trimethylsilylbeneylsulphamates as treatments for diseases of bone loss | |
| AU2007905975A0 (en) | Treatment of metabolic disease 2 | |
| AU2007905974A0 (en) | Treatment of metabolic disease 1 | |
| GB0700577D0 (en) | Composition for heart disease |